DNTH — Dianthus Therapeutics, Inc. /DE/
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1690585 ·
Last close
$86.98
Market Cap
$4.90B
52W High
$117.88
52W Low
$35.84
ADV30
901,788
Next earnings
2026-11-04
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 1,210,000 | — | -58,472,000 | -46,643,000 | 1,276,252,000 | 55,686,000 | 34,823,000 |
| Jun 2026 | 761,000 | — | -61,482,000 | -50,215,000 | 1,213,271,000 | 110,549,000 | 41,246,000 |
| Mar 2026 | 463,000 | — | -46,533,000 | -40,834,000 | 1,246,884,000 | 627,667,000 | 45,570,000 |
| Dec 2025 | 284,000 | — | -69,541,000 | -64,432,000 | 530,922,000 | 51,087,000 | 37,521,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-175,154,000
Investing CF
$-687,161,000
Financing CF
$862,146,000
CapEx
$-697,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.99
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-474,421,000
Inventory
—
Receivables
$582,000
ST Investments
$782,097,000
EBIT TTM
$-236,028,000
Pretax Income TTM
$-202,124,000
Interest Exp TTM
—
Analysts
16
Yahoo Snapshot (yfinance, live)
Total Revenue
$2,718,000
EBITDA
$-235,895,008
Free Cash Flow
$-109,141,504
Enterprise Value
$4,008,007,680
Total Cash
$837,782,976
Total Debt
$1,208,000
Shares Out
56,312,712
Trailing EPS
$-4.08
Book Value
$22.05
ROE
-22.6%
ROA
-15.9%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 2,036,000 | -177,933,000 | -162,337,000 | 530,922,000 | 37,521,000 | 493,401,000 | -129,060,000 |
| Dec 2024 | 6,235,000 | -101,864,000 | -84,969,000 | 374,008,000 | 21,531,000 | 352,477,000 | -78,180,000 |
| Dec 2023 | 2,826,000 | -48,174,000 | -43,555,000 | 179,405,000 | 10,535,000 | 168,870,000 | -36,861,000 |
| Dec 2022 | 6,417,000 | -29,705,000 | -28,476,000 | 83,110,000 | 9,454,000 | 73,656,000 | -29,070,000 |
TTM Snapshot
Revenues TTM
$1,904,000
NetIncome TTM
$-192,246,000
OpCashFlow TTM
—
Assets (Latest)
$1,213,271,000
Forward EPS
$-4.61
Max Pain — expiry 2026-12-18
max pain strike: $75.00 · spot: $83.98 · call oi: 1,063 · put oi: 1,501Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| TVTX | Travere Therapeutics, Inc. | $4.91B | $51.10 | — |
| ERAS | Erasca, Inc. | $4.87B | $13.89 | — |
| COGT | Cogent Biosciences, Inc. | $4.85B | $27.85 | — |
| PTCT | PTC THERAPEUTICS, INC. | $5.04B | $60.36 | — |
| LQDA | Liquidia Corp | $5.11B | $56.73 | — |
News headlines (Yahoo Finance, 1h cache)
Wall Street Analysts See a 61.23% Upside in Dianthus Therapeutics, Inc. (DNTH): Can the Stock Really Move This High?
2026-11-09 13:55 · Yahoo
Dianthus Therapeutics, Inc. (DNTH) Reports Q3 Loss, Beats Revenue Estimates
2026-11-04 21:15 · Yahoo
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 2026 Financial Results
2026-11-04 21:01 · Yahoo
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-11-02 22:00 · Yahoo
Dianthus Therapeutics to Participate in Five Investor Conferences During November
2026-11-02 21:01 · Yahoo
Dianthus Therapeutics (DNTH) Stock May Be Above Fair Value Following Its 5x Run
2026-10-20 09:15 · Yahoo
Dianthus Therapeutics Named to Fortune’s 2026 Best Workplaces in BioPharma List Amid Company Expansion
2026-10-13 13:52 · Yahoo
Dianthus Therapeutics Recognized Among Fortune’s 2026 Best Workplaces In BioPharma
2026-10-13 12:45 · Yahoo
Dianthus Therapeutics Highlights Claseprubart Data Presentations Planned for 2026 AANEM Annual Meeting
2026-09-29 12:00 · Yahoo
Can Dianthus Therapeutics (DNTH) Stay Undervalued Following Its $500 Million Stock Offering?
2026-09-24 08:10 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.